United States News All stories

Dave & Buster's Entertainment (NASDAQ:PLAY) reported financial results for the fourth quarter and fiscal year ended February 1, 2026, on Tuesday, March 31, 2026.

nCino (NASDAQ:NCNO) reported robust financial results for its fiscal year 2026 on Tuesday, March 31, 2026, demonstrating continued momentum in the global digital transformation of banking.

Chagee Holdings (NASDAQ:CHA) announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31, 2026.

Phoenix Asia Holdings (NASDAQ:PHOE) reported unaudited financial results for the six-month period ended September 30, 2025, on Tuesday, revealing a challenging start to the fiscal year defined by compressed margins and lower top-line volume.

Bitfarms (NASDAQ:BITF) announced transformative full-year 2025 financial results and a major corporate restructuring on Tuesday, March 31, 2026, headlined by a shareholder-approved plan to redomicile to the United States and rebrand as Keel Infrastructure.

Novo Nordisk (NYSE:NVO) announced a strategic shift in its commercial approach on Tuesday, March 31, 2026, launching a multi-month subscription program for its flagship obesity medication, Wegovy.

McCormick & Company (NYSE:MKC) and Unilever announced a landmark agreement on Tuesday, March 31, 2026, to combine McCormick with Unilever’s global foods business.

Forum Markets (NASDAQ:FRMM), a fintech company focused on real-world asset tokenization, reported its fourth-quarter and full-year 2025 financial results and provided 2026 guidance on its scaling RWA platform.

Reading International (NASDAQ:RDI), a company engaged in cinema exhibition and real estate development, reported its fourth-quarter and full-year 2025 financial results.

OS Therapies (NYSE:OSTX) announced on Tuesday, March 31, 2026, that it has reached a pivotal regulatory milestone by submitting its Phase 2b clinical and biomarker data to the U.S. Food and Drug Administration (FDA) for a formal Pre-BLA (Biologics License Application) meeting.

NervGen Pharmaceutics (NASDAQ:NGEN) reported its full-year 2025 financial and operational results on Tuesday, March 31, 2026, marking a definitive shift toward pivotal-stage clinical development.

Cadrenal Therapeutics (NASDAQ:CVKD) reported its fourth-quarter and full-year 2025 financial results on Tuesday, March 31, 2026, marking a critical transition from mid-stage development to pivotal Phase 3 readiness for its lead candidate, CAD-1005.

Canton Strategic Holdings (NASDAQ:CNTN) reported its full-year 2025 financial results on Tuesday, March 31, 2026, marking its first complete fiscal year since pivoting to a dedicated digital asset and blockchain infrastructure strategy.

SPAR Group (NASDAQ:SGRP) issued optimistic financial guidance for fiscal year 2026 on Tuesday, March 31, 2026, signaling a major turn toward higher profitability and operational efficiency.

Scholar Rock (NASDAQ:SRRK) announced on Tuesday, March 31, 2026, that it has officially resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab.

SCYNEXIS (NASDAQ:SCYX) announced a transformative strategic shift on Tuesday, March 31, 2026, transitioning its core focus toward rare kidney diseases through a significant asset acquisition and a major equity financing.

AIRO Group Holdings (NASDAQ:AIRO) announced financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, highlighting significant double-digit revenue growth and a return to break-even profitability.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported robust financial and operational results for the full year 2025 on Tuesday, March 31, 2026, headlined by a 65% surge in net product revenue.

MiNK Therapeutics (NASDAQ:INKT) reported its fourth-quarter and full-year 2025 financial results on Tuesday, detailing a well-capitalized path toward several major clinical readouts in the coming year.

Palvella Therapeutics (NASDAQ:PVLA) reported transformative full-year 2025 financial results and a significant corporate update on March 31, 2026, headlined by the successful clinical validation of its lead rare disease program.

BOS (NASDAQ:BOSC) reported record-breaking financial results for the full year 2025 on Tuesday, characterized by significant double-digit growth across all key profitability metrics.

Soligenix (NASDAQ:SNGX) reported financial results for the full year ended December 31, 2025, on March 31, 2026, emphasizing a clear pathway toward critical late-stage clinical data readouts.

Keenova Therapeutics (NYSE:MNK) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, marking its first full quarter as a combined branded therapeutics entity following the merger of Mallinckrodt and Endo.

Eli Lilly and Company (NYSE:LLY) announced a definitive agreement on Tuesday to acquire Centessa Pharmaceuticals, marking a significant strategic entry into the sleep medicine market.